Next Treatments
Back to Eczema

lunsekimig

TypeInjection StagePhase 2 Latest updateApr 9, 2026Phase 2 study completed

What stands out

New approach in eczema

  • Acts on TSLP, which no approved eczema treatment currently does; also targets IL-13 (like Adbry and Ebglyss)
  • Binds to IL-13 (a signal molecule that plays a role in allergic inflammation) and TSLP (a signal that helps activate and attract immune cells)
Derived from FDA substance registry · UniProt P35225 · UniProt Q969D9 ·
11 US eczema labels (Adbry, Ebglyss, Cibinqo, Eucrisa, Adquey, Dupixent, Nemluvio, Zoryve, Opzelura, Vtama, Rinvoq)
· This is a summary of public records for informational purposes only. It is not medical advice.

History

Earliest recorded event: Jan 30, 2025. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.

  • Apr 9, 2026Phase 2 trial completedA Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis ClinicalTrials.gov NCT06790121
  • Feb 12, 2026Phase 2 main data collectedA Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis ClinicalTrials.gov NCT06790121
  • Jan 30, 2025Phase 2 trial startedA Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis ClinicalTrials.gov NCT06790121

Sources

Trials
  • NCT06790121Also registered: U1111-1299-1958; 2024-511549-20